Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last C$0.39 CAD
Change Today +0.01 / 2.63%
Volume 29.5K
CZO On Other Exchanges
As of 3:55 PM 05/1/15 All times are local (Market data is delayed by at least 15 minutes).

ceapro inc (CZO) Snapshot

Previous Close
Day High
Day Low
52 Week High
12/3/14 - C$0.75
52 Week Low
05/20/14 - C$0.09
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for CEAPRO INC (CZO)

Related News

No related news articles were found.

ceapro inc (CZO) Related Businessweek News

No Related Businessweek News Found

ceapro inc (CZO) Details

Ceapro Inc., a biotechnology company, develops, commercializes, and markets health and wellness products, and technology relating to plant extracts in Canada, the United States, Germany, and other countries. The company markets natural active ingredients, including beta glucan, avenanthramides, oat powder, oat oil, oat peptides, and lupin peptides to personal care, cosmetic, medical, and animal health industries through its distribution partners and direct sales; and veterinary therapeutic products, such as an oat shampoo, an ear cleanser, and a dermal complex/conditioner for veterinarians in Japan and Asia. Its products and technologies under research and development, or pre-commercial stage include CeaProve, a diabetes test meal to screen pre-diabetes and to confirm diabetes diagnosis; a drug delivery platform using its beta glucan technology delivers compounds for uses ranging from wound care and therapy to skin care treatments that reduce the signs of aging; an extension to the active ingredients product range; various novel manufacturing technologies; and new oat variety and technologies to increase the content of avenanthramides. The company was incorporated in 1997 and is headquartered in Edmonton, Canada.

Founded in 1997

ceapro inc (CZO) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: C$252.0K
Chief Financial Officer, Vice President of Fi...
Total Annual Compensation: C$147.0K
Compensation as of Fiscal Year 2013.

ceapro inc (CZO) Key Developments

Ceapro Inc. Appoints Ulrich Kosciessa to Board of Directors

Ceapro Inc. has appointed international pharmaceutical industry expert, Ulrich Kosciessa, Ph.D., to its Board of Directors. Dr. Kosciessa has over two decades of research, business development and marketing leadership experience. He is a member of the Executive Management Board of Medac GmbH., Managing Director of Medac International, and Chairman of the Board of Medac Pharma Inc. Throughout his successful management career at Medac, Dr. Kosciessa has formed several subsidiaries and affiliates as well as established a network of global partners, growing the company's international business more than 50% since 2005. In addition, since 2006 Dr. Kosciessa has also served as Chief Executive Officer of Photonamic. From 2006 to 2008, Dr. Kosciessa also served as Chief Executive Officer at Immune Laboratory of Hannover.

Ceapro Inc. Reports Consolidated Earnings Results for the Year Ended December 31, 2014

Ceapro Inc. reported consolidated earnings results for the year ended December 31, 2014. For the year, the company reported total revenues of $8,890,256 as compared to $6,524,062 for the same period a year ago, an increase of 36% primarily as a result of higher sales volumes of avenanthramides and oat oil. Total revenues were also positively impacted by a stronger U.S. dollar relative to the Canadian dollar. Net income was $1,593,795 compared to a net income of $175,808 for the same period in 2013. Income from operations were $1,999,717 compared to $447,027 a year ago. Total comprehensive income for the year was $1,593,795 compared to $158,892 a year ago. Basic and diluted income per share was $0.03. The best financial results were achieved because of the record demand for the product, avenanthramides. Importantly, these impressive results were realized while transitioning to a new site and focusing the resources on selected product development which the company believes will be integral to the growth and expansion plans in the coming years.

Ceapro Inc. Auditor Raises 'Going Concern' Doubt

Ceapro Inc. filed its Annual on Apr 22, 2015 for the period ending Dec 31, 2014. In this report its auditor, Grant Thornton, gave an unqualified opinion expressing doubt that the company can continue as a going concern.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CZO:CN C$0.39 CAD +0.01

CZO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CZO.
View Industry Companies

Industry Analysis


Industry Average

Valuation CZO Industry Range
Price/Earnings 14.6x
Price/Sales 2.6x
Price/Book 10.9x
Price/Cash Flow 14.4x
TEV/Sales 2.2x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CEAPRO INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at